Ryoncil (remestemcel-l-rknd) NDC 73648-111

NDC codes

FDA NDC Directory

Product NDC (as listed)73648-111Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73648-0111Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73648-111-01	73648011101	1 KIT in 1 CARTON (73648-111-01) * 1 VIAL, PLASTIC in 1 CARTON / 3.8 mL in 1 VIAL, PLASTIC * 1 mL in 1 POUCHMarketed from Mar 17, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ryoncil
Generic name (nonproprietary): remestemcel-l-rknd
Dosage form: Kit
Labeler: Mesoblast
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125706
Marketing start: Mar 17, 2025
Listing expires: Dec 31, 2026
Identifiers: Product ID 73648-111_59dc6f33-2845-4182-81ae-04d34d7f2204SPL ID 59dc6f33-2845-4182-81ae-04d34d7f2204SPL set ID a4e0918f-7444-4694-adeb-d38d98345659RxCUI 797544, 2700771, 2700778, 2706549, 2706550, 2706551, 2706552, 2706553, 2706554, 2706555, 2706556, 2706557, 2706558, 2706559, 2706560, 2706561, 2706562, 2706563, 2706564, 2723916, 2723917, 2723918, 2723919, 2723920, 2723921, 2723922, 2723923

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N473648011101 followed by a unit qualifier and the quantity

Package 73648-0111-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 11, 2025.

Indications (excerpt from the label)

RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. RYONCIL is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 125706

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 125706
Product	Strength	Form · route	Labeler	Product NDC
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-114
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-112
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-113
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-118
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-115
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-116
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-117
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-122
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-119
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-120
Ryoncilremestemcel-l-rknd	—	Kit	Mesoblast	73648-121